"I" . . . . "3"^^ . "79367" . . "Immunotherapy for prostate cancer"@en . "11130" . "Imunoterapie karcinomu prostaty"@cs . "14" . . "Prostate cancer is among the most common types of cancer disease in men. If there is a relapse of the disease after primary radical therapy or the disease is diagnosed in an advanced stage, therapeutic options are limited. Given this, immunotherapy appears to be another promising treatment modality. The development of cancer disease is a multistage process of a complex nature wherein the tumour cells themselves represent a very heterogeneous population put into the context of a microenvironment of non-tumour cells and tissues forming a complex tumour %22ecosystem%22. The immune system is capable of controlling tumour cell growth in early stages of tumour development. With advanced tumour growth, immune mechanisms become more or less paralysed and, in fact, frequently have a promoting effect on tumour cell proliferation. In order to be successful, anticancer therapy must take into consideration all the complex aspects of interaction of the immune system and tumour cells, including the microenvironment. The article deals with dendritic cell-based tumour vaccines that are tested in patients with various stages of prostate cancer as immunotherapy in combination with other treatment modalities."@en . "4"^^ . . "CZ - \u010Cesk\u00E1 republika" . "http://www.urologiepropraxi.cz/pdfs/uro/2013/01/04.pdf" . "Urologie pro praxi" . "[63372C95164A]" . . "RIV/00216208:11130/13:10195924!RIV14-MSM-11130___" . "Immunotherapy for prostate cancer"@en . "1213-1768" . . . "Podrazil, Michal" . "Imunoterapie karcinomu prostaty"@cs . "RIV/00216208:11130/13:10195924" . "Karcinom prostaty pat\u0159\u00ED mezi nej\u010Dast\u011Bj\u0161\u00ED n\u00E1dorov\u00E1 onemocn\u011Bn\u00ED u mu\u017E\u016F. Pokud dojde k relapsu onemocn\u011Bn\u00ED po prim\u00E1rn\u00ED radik\u00E1ln\u00ED terapii nebo pokud je onemocn\u011Bn\u00ED diagnostikov\u00E1no v pokro\u010Dil\u00E9m stadiu, jsou mo\u017Enosti l\u00E9\u010Dby omezen\u00E9. Proto se imunoterapie jev\u00ED jako dal\u0161\u00ED perspektivn\u00ED l\u00E9\u010Debn\u00E1 modalita. Vznik n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED je mnohastup\u0148ov\u00FD proces komplexn\u00ED povahy, v n\u011Bm\u017E samotn\u00E9 n\u00E1dorov\u00E9 bu\u0148ky p\u0159edstavuj\u00ED velmi heterogenn\u00ED populaci zasazenou do kontextu mikroprost\u0159ed\u00ED nen\u00E1dorov\u00FDch bun\u011Bk a tk\u00E1n\u00ED tvo\u0159\u00EDc\u00EDch slo\u017Eit\u00FD n\u00E1dorov\u00FD %22ekosyst\u00E9m%22. Imunitn\u00ED syst\u00E9m je schopen kontrolovat r\u016Fst n\u00E1dorov\u00FDch bun\u011Bk v ran\u00FDch stadi\u00EDch vzniku n\u00E1doru. S pokro\u010Dil\u00FDm r\u016Fstem n\u00E1doru se imunitn\u00ED mechanizmy v\u00EDcem\u00E9n\u011B paralyzuj\u00ED a mnohdy maj\u00ED naopak podp\u016Frn\u00FD \u00FA\u010Dinek ve prosp\u011Bch proliferace n\u00E1dorov\u00FDch bun\u011Bk. Aby byla protin\u00E1dorov\u00E1 terapie \u00FAsp\u011B\u0161n\u00E1, mus\u00ED zohled\u0148ovat v\u0161echny komplexn\u00ED aspekty interakce imunitn\u00EDho syst\u00E9mu a n\u00E1dorov\u00FDch bun\u011Bk v\u010Detn\u011B mikroprost\u0159ed\u00ED. V \u010Dl\u00E1nku je probr\u00E1na problematika n\u00E1dorov\u00FDch vakc\u00EDn zalo\u017Een\u00FDch na dendritick\u00FDch bu\u0148k\u00E1ch, kter\u00E9 se testuj\u00ED u pacient\u016F s karcinomem prostaty v r\u016Fzn\u00FDch stadi\u00EDch jako imunoterapie v kombinaci s dal\u0161\u00EDmi l\u00E9\u010Debn\u00FDmi modalitami."@cs . . "Imunoterapie karcinomu prostaty" . . . "Karcinom prostaty pat\u0159\u00ED mezi nej\u010Dast\u011Bj\u0161\u00ED n\u00E1dorov\u00E1 onemocn\u011Bn\u00ED u mu\u017E\u016F. Pokud dojde k relapsu onemocn\u011Bn\u00ED po prim\u00E1rn\u00ED radik\u00E1ln\u00ED terapii nebo pokud je onemocn\u011Bn\u00ED diagnostikov\u00E1no v pokro\u010Dil\u00E9m stadiu, jsou mo\u017Enosti l\u00E9\u010Dby omezen\u00E9. Proto se imunoterapie jev\u00ED jako dal\u0161\u00ED perspektivn\u00ED l\u00E9\u010Debn\u00E1 modalita. Vznik n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED je mnohastup\u0148ov\u00FD proces komplexn\u00ED povahy, v n\u011Bm\u017E samotn\u00E9 n\u00E1dorov\u00E9 bu\u0148ky p\u0159edstavuj\u00ED velmi heterogenn\u00ED populaci zasazenou do kontextu mikroprost\u0159ed\u00ED nen\u00E1dorov\u00FDch bun\u011Bk a tk\u00E1n\u00ED tvo\u0159\u00EDc\u00EDch slo\u017Eit\u00FD n\u00E1dorov\u00FD %22ekosyst\u00E9m%22. Imunitn\u00ED syst\u00E9m je schopen kontrolovat r\u016Fst n\u00E1dorov\u00FDch bun\u011Bk v ran\u00FDch stadi\u00EDch vzniku n\u00E1doru. S pokro\u010Dil\u00FDm r\u016Fstem n\u00E1doru se imunitn\u00ED mechanizmy v\u00EDcem\u00E9n\u011B paralyzuj\u00ED a mnohdy maj\u00ED naopak podp\u016Frn\u00FD \u00FA\u010Dinek ve prosp\u011Bch proliferace n\u00E1dorov\u00FDch bun\u011Bk. Aby byla protin\u00E1dorov\u00E1 terapie \u00FAsp\u011B\u0161n\u00E1, mus\u00ED zohled\u0148ovat v\u0161echny komplexn\u00ED aspekty interakce imunitn\u00EDho syst\u00E9mu a n\u00E1dorov\u00FDch bun\u011Bk v\u010Detn\u011B mikroprost\u0159ed\u00ED. V \u010Dl\u00E1nku je probr\u00E1na problematika n\u00E1dorov\u00FDch vakc\u00EDn zalo\u017Een\u00FDch na dendritick\u00FDch bu\u0148k\u00E1ch, kter\u00E9 se testuj\u00ED u pacient\u016F s karcinomem prostaty v r\u016Fzn\u00FDch stadi\u00EDch jako imunoterapie v kombinaci s dal\u0161\u00EDmi l\u00E9\u010Debn\u00FDmi modalitami." . "Imunoterapie karcinomu prostaty" . . "Bart\u016F\u0148kov\u00E1, Ji\u0159ina" . "1" . . "\u0160p\u00ED\u0161ek, Radek" . . "dendritic cells; immunotherapy; cancer immunosurveillance; immune syst\u00E9m; prostate cancer"@en . . "3"^^ . . . .